Sign In
Buy RAPT
$58.02
+0 (+0%)
At Close: Jun 01, 2026
Implied Volatility Surging for RAPT Therapeutics (RAPT) Stock Options
09:46am, Wednesday, 19'th May 2021
Investors need to pay close attention to RAPT Therapeutics (RAPT) stock based on the movements in the options market lately.
RAPT THERAPTICS (RAPT) Reports Q1 Loss, Misses Revenue Estimates
10:31am, Tuesday, 11'th May 2021
RAPT THERAPTICS (RAPT) delivered earnings and revenue surprises of -26.92% and -28.12%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
RAPT Therapeutics Reports First Quarter 2021 Financial Results
08:00am, Tuesday, 11'th May 2021
SOUTH SAN FRANCISCO, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing a
Do Options Traders Know Something About RAPT Therapeutics (RAPT) Stock We Don't?
08:20am, Monday, 12'th Apr 2021
Investors need to pay close attention to RAPT Therapeutics (RAPT) stock based on the movements in the options market lately.
Connect Biopharma Pursues $150 Million U.S. IPO Plan
03:43pm, Tuesday, 16'th Mar 2021
Connect Biopharma Pursues $150 Million U.S. IPO Plan
RAPT THERAPTICS (RAPT) Reports Q4 Loss, Misses Revenue Estimates
10:37am, Thursday, 11'th Mar 2021
RAPT THERAPTICS (RAPT) delivered earnings and revenue surprises of 3.70% and -36.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
RAPT Therapeutics to Report Promising Preclinical Studies Supporting its Pipeline of Immunotherapy Platforms at AACR
04:30pm, Wednesday, 10'th Mar 2021
SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing
RAPT Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
08:00am, Monday, 23'rd Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing
RAPT Therapeutics Reports Third Quarter 2020 Financial Results
08:00am, Monday, 16'th Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing
RAPT Therapeutics Reports Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications
07:30am, Monday, 16'th Nov 2020
-Evidence of Monotherapy and Combination Activity in Charged Tumor Types--Company Advances Several Cohorts into Phase 2 Expansions--Conference Call and Webcast to be Held at 8:30 a.m. ET Today-
RAPT Therapeutics to Announce Initial Data from Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications
07:30am, Sunday, 15'th Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing
RAPT Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
08:00am, Friday, 13'th Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing
